4Lun·

Myomo Inc. "The cyborg gamble with the government seal of approval."

Imagine your arm is "numb" or paralyzed after a stroke. The brain sends commands, but the muscles in the arm no longer respond. This is exactly where Myomo technology (MyoPro) comes into play. It is not just a "support splint", it is active mechatronics.

Unfortunately, the statistics are merciless. Worldwide, almost 94 million people with the consequences of a stroke. Every year there are around 12 million new cases are added. One in four adults over the age of 25 will suffer a stroke in their lifetime.

The demographic pressure: Our societies are ageing and risk factors such as high blood pressure, diabetes and lack of exercise are increasing globally. This means that the need for effective rehabilitation solutions for paralyzed limbs that are suitable for everyday use is not decreasing - it is growing dramatically.

A brief clarification: I've been invested since today because I think the story is cool and this is a gamble with potential.

1. what the company does

Myomo $MYO (-0,89 %) builds medical robotics, specializing in the upper extremities. Its main product is the "MyoPro" splint - a wearable exoskeleton. When patients can no longer control their arm due to a stroke, MS or nerve injury, the MyoPro reads the remaining, extremely weak electrical signals on the skin (EMG). The finest CNC-milled joints and tiny servomotors then take over the mechanical movement. This is not just theory, this thing literally brings patients out of paralysis.

The highlight: Sensors recognize the patient's intention - does he want to open his hand, bend his elbow or grasp something? - and tiny, high-precision motors and gears support this exact movement. The patient controls the robotic arm with his own will. It is literally a neural bridge between what the patient wants and what they can physically do.

2. key figures, data & facts (real-time)

Current share price: ~ 1.03 $* Market capitalization: ~ 35 Mio.$ (An absolute micro-cap!)
Price-earnings ratio (P/E ratio): Negative (currently no profits yet)
Price-to-sales ratio (P/S ratio): ~ 1,8
Price-to-book ratio (P/B ratio): ~ 2,5
Dividend yield: 0,0 %

In other recent news, Myomo Inc. presented its results for the first quarter of 2026, beating expectations for both earnings per share (EPS) and revenue. The company achieved EPS of -$0.07, which was above the forecast of -$0.12. Myomo also reported revenue of $10.1 million, exceeding the expected $9.24 million. These figures reflect a positive business development for the company in the quarter.

3. check against our established formulas

Core quality formula: Sales growth is currently picking up steeply (well over 30%), but the operating margin is still deep red. Score < 15. *
Conclusion on the AOK filter: Fails mercilessly as a core investment. This is a pure B-side satellite for the gambler's corner. We are buying the expectation that the extreme sales growth will turn the red margin into positive territory in the next 24 months.

4 ROIC (Return on Invested Capital)

Currently negative. The development of medical technology and the expensive battle for approvals have tied up a lot of capital. Now the phase begins in which this invested capital must finally yield a return.

5. stock-based compensation (SBC) ratio & dilution

Dilution is always the biggest risk for micro-caps in the medical sector. In the past, Myomo often had to issue new shares to ensure its survival. However, due to its new status with the health insurance companies (more on this in point 7), hard dollars are now flowing into the company's coffers. The risk of dilution has fallen massively.

6. net debt / EBITDA ratio

EBITDA is still negative, which is why this key figure does not traditionally apply. However, Myomo has recently raised fresh capital and currently has a solid enough balance sheet to scale production without an overwhelming debt burden.

7. future prospects & competition

The game changer: The US Department of Health and Human Services (Medicare) has officially included the MyoPro in the Part B category and is now paying for the device.

In the past, Myomo had to laboriously find private patients; now the state pays.

Competition: Other companies also build exoskeletons, but focus almost exclusively on the legs (paraplegia). When it comes to arms and hands, Myomo has a truly unique selling point, almost a moat.

8. chart analysis (last months)

Typical penny stock roller coaster. Over the last 12 months, the share has often fluctuated wildly between $0.60 and $2.50, driven by the news surrounding Medicare approval. It is currently consolidating just above the important 1 dollar mark. It must hold this level to avoid being warned by the NASDAQ.

9 Management & CEO statements

CEO Paul Gudonis has proven that he has staying power. He has navigated the company through years of brutal FDA and Medicare approvals. The management is now completely focused on expanding production capacity in order to work through the waiting lists of patients.

Addendum Thanks to @jkb92, there was recent insider buying: https://m.de.investing.com/news/insider-trading-news/myomodirektor-kirk-thomas-f-kauft-aktien-im-wert-von-68242--93CH-3488408?ampMode=1

10th analyst consensus

Micro-caps like $MYO (-0,89 %) are ignored by the big Wall Street banks. The few small boutique analysts (such as H.C. Wainwright) who cover the stock are currently shouting "Strong Buy" with price targets between $3.00 and $5.00.

11. bargain hunter list (entry zones)

Current (~$1.03): Perfect speculative entry for play money. The fundamentally most important knot (payment by health insurance companies) has burst.

Support zone: There is a hard floor at $0.80. If it falls below this level on a sustained basis, the story will be ruined for the time being.

12 Possible replacements (alternatives)

If you believe in the robotics trend in medicine but would rather invest in legs than arms, take a look at Lifeward (LFWD) IL0011331076.

Also quoted in the single-dollar range.

13. detailed report (my conclusion)

Myomo is a smart hardware gamble. The company has successfully survived the "death zone" for small medtech companies - the quest for regulatory reimbursement. Now it's time for implementation. The demand for mechatronic aids for stroke patients is huge.

We have a technology here that alleviates real human suffering, has a huge and growing target group and has finally made the leap into state reimbursement. This is not a "story without substance" - this is medical robotics that is now making the leap to scale. A highly exciting gamble that has the fundamental potential to grow from a penny stock to a real MedTech giant.

An absolute top candidate for a limited play money budget on the B-side.

State-Funded Recovery: With US Medicare approval, Myomo has risen from "niche gadget for the rich" to recognized standard medical product for home use.

Cost-effectiveness: This is even profitable for health insurance companies. A patient who can eat, wash or grasp simple things independently again with MyoPro needs fewer expensive nursing staff and is less dependent on external help.

@Multibagger

@Tenbagger2024

@Get_Rich_or_Die_Tryin

and of course everyone else :)

27 Comentarios

jkb92@jkb92

4Lun

It's really cool what micro-caps you always land. There must have been some insider buying recently: https://m.de.investing.com/news/insider-trading-news/myomodirektor-kirk-thomas-f-kauft-aktien-im-wert-von-68242--93CH-3488408?ampMode=1

•

jkb92@jkb92

4Lun

@jkb92 also put in 500 :)

•

Raketentoni@Raketentoni

4Lun

@jkb92 Ah okay, I had forgotten, with your permission, I'll include the link :)

•

Raketentoni@Raketentoni

4Lun

@jkb92 I am also specifically looking for investments that deal with niches, away from the AI hype.
But thanks for the praise :) that motivates me

•

jkb92@jkb92

4Lun

@Raketentoni clear :)

•

jkb92@jkb92

4Lun

@Raketentoni Yes, I think that's cool. Dessert Control is now moving in the right direction again after the strong dip.

•

Raketentoni@Raketentoni

4Lun

@jkb92 Today it's going up again, by the way, nice report on why big players are also getting in:

https://finance.yahoo.com/markets/stocks/articles/myomo-myo-shows-fast-paced-125502252.html

@Get_Rich_or_Die_Tryin @Tenbagger2024

•

Tenbagger-Capital@Tenbagger-Capital

4Lun

@Raketentoni I also see a lot of potential here. I think we could perhaps also benefit from the problems that occurred at Otto Bock. There should also be a lack of confidence in Otto Bock. And then investors will look for new players in the sector. But that also speaks for the company. Is there also a humanoid robot area here, it would be exciting to be able to control a humanoid by thought

•

Raketentoni@Raketentoni

4Lun

@Tenbagger2024 But Otto Bock makes prostheses. Myomo makes your arm or leg usable again, a completely different approach. :)

••

Tenbagger-Capital@Tenbagger-Capital

4Lun

@Raketentoni but I think I once read that Otto Bock is also in this area. But I'm not 100% sure about that.

••

Raketentoni@Raketentoni

4Lun

@Tenbagger2024 Although both companies work in the field of mobility aids for people with physical disabilities, the differences from an investor's point of view - and technologically - could hardly be greater.Here is the direct comparison between the giant Ottobock and your investment Myomo (MYO):1. The business model & The size (Dino vs. Speedboat)Ottobock (The "medium-sized giant"): Ottobock is the global market leader in prosthetics (artificial limbs) and orthotics (splints/corsets). The company is over 100 years old, has over 9,000 employees and an annual turnover of well over one billion euros. They have a broad base: They make everything from mechanical wheelchairs to carbon prostheses for Paralympic athletes to highly complex computer-controlled leg systems (such as the famous C-Brace). Myomo (your investment): Myomo is a highly specialized medical robotics company (wearable robotics) from the USA. Compared to Ottobock, Myomo is tiny (micro-cap). They basically focus on a single, groundbreaking product: the MyoPro arm brace. 2. the technological difference (replacement vs. "power steering" for paralyzed arms)Ottobock's focus: Ottobock has traditionally been gigantically strong in replacing lost limbs (prosthetics). When they build splints (orthoses), these are mostly used for stabilization (e.g. after a stroke for the legs). The focus of Myomo (MyoPro): Myomo attacks where Ottobock had little to offer for a long time: paralyzed or extremely weakened but still present arms (e.g. after a stroke, traumatic brain injury or plexus palsy). The magic behind it: The MyoPro brace uses non-invasive sensors on the skin to read the tiny electromyographic (EMG) nerve signals that the brain sends to the paralyzed arm. Built-in electric motors immediately amplify this signal and move the arm in the way the patient actually intended. It is a kind of "power steering" for paralyzed limbs. 3. latest development: not enemies, but partners! the best thing about your investment is that the two companies don't tear each other apart, but complement each other perfectly. hot news from may 2026: Myomo just announced a massive expansion of its partnership with Ottobock a few weeks ago. The MyoPro arm orthoses are now being sold and fitted in Ottobock Care clinics across the USA. Ottobock is therefore using Myomo to position its own clinics as the absolute market leader for neuro-robotic solutions, as they have nothing comparable on the shelves, even in the upper extremity (arm) sector. In turn, this gives Myomo immediate access to Ottobock's gigantic sales and clinic network.

••

Ver todas las 3 respuestas adicionales

Get_Rich_or_Die_Tryin@Get_Rich_or_Die_Tryin

4Lun

Hi there, Rob here, the cash flow killer from the north. So you want me to give your buddy Raketentoni and his loyal order recipient Mr. Prompt a good ribbing? No problem. If the two of them want to sell me a place like **Myomo Inc (MYO)** as the next hot shit, they've done the math without the bouncer.
The gentlemen "story investors" are probably just looking at the shiny exoskeletons and dreaming of the million, while I have to look at the misery in the books. Fasten your seatbelts, Toni and Mr. Prompt - now the box will be dissected completely incorruptibly.

Here's the fiery **final boss check** for Myomo!

## 1. financial check & multiples

The stock is bouncing around on the **NYSE American**. The current daily price (closing price May 22, 2026) has been compressed to **0.96 USD**. At the current exchange rate of 1.08 USD/EUR, this corresponds to **0.89 EUR** - a genuine penny stock in the nano-cap sector (market capitalization: a mere 35 million USD).

*Note: Values in millions of USD (except multiples)*.

| Key figure | Actual year (FY2025) | Guidance / Expectation (FY2026) | Outlook (FY2027e) |

| **Revenue** | 24.1 | 43.0 - 46.0 | 58.0 |

| **Sales growth** | +27 % | +82 % (driven by Medicare) | +30 % |

| EBITDA (Adj.)** | -1.8 | -1.0 (break-even in sight) | 3.5 |

| **KGV (GAAP)** | Negative (loss) | Negative | ~14.0 |

| **Net Debt / EBITDA** | Net Cash (~15.7m) | Net Cash | Net Cash |

| **EK ratio** | 74% | ~71% | ~73% |

| **ROE / ROIC** | Negative | Negative | 9.5 % / 12.0 % |

> **Rob's mustard on the balance sheet:** *Listen up, Raketentoni and Mr. Prompt: The bare figures show that the company has never generated a cent of real net profit. After all, according to the Q1 report (May 7, 2026), they have USD 15.7 million cash on hand and no bank debt. But the market capitalization of USD 35 million shows that the market doesn't trust the company. There will not be a P/E ratio until 2027 - if the lights don't go out by then.*

## 2nd margin ladder (earnings power)

**Gross margin (Q1 2026):** 68.2 % (Hardware is profitable thanks to a high average price of USD 58,800 per unit).

* Net margin (Q1 2026):** -29.7 % (USD 3.0 million net loss on USD 10.1 million revenue).

* **FCF margin (Q1 2026):** **-21.8%** (USD 2.2m operating cash burn).

** **Veto criticism (gold standard of 15% badly missed):** Guys, look at this! An FCF margin of minus 21.8% in the latest quarter. That's not a moat, that's an open barn door through which the money is being burned. Why does the veto take effect and not kick Myomo out immediately? Because the management is turning the corner: revenue from recurring patient sources has exploded from 25% to 49%. But as long as there is no positive cash flow, the company will remain an unprofitable capital guzzler for me.

## 3rd Piotroski F-Score (Bundled)

**Overall score: 4 out of 9 points** - Typical condition for a company in intensive care.

** **Category profitability (1/4):** Operating cash flow and net income are deep red. Only the slightly reduced loss saves the consolation point.

** **Category Financing & Liquidity (2/3):** No debt, liquidity is sufficient for the time being, but the number of shares is increasing due to the constant issue of shares to finance growth. Existing shareholders are diluted.

* Operational Efficiency (1/2):** Gross margin looks good, but asset turnover is a joke due to low volume.

## 4. dividend & shareholder check

** **Dividend yield / payout:** 0.0 % - Anyone looking for dividends here still believes in Santa Claus.

** **Buybacks & insider transactions:** No buybacks. The management prefers to be handsomely rewarded with stock options (SBC) for the meager results instead of putting their own money into the company.

## 5. regions & moat (moat)

### Geography

* **USA:** ~80% (The focus, as this is where the health insurance money is).

* **International (mainly Germany):** ~20 % (At least the German business picked up to around USD 2m in Q1 because the bureaucracy here seems to have been oiled a little).

### Moat & market shares

Myomo has a unique product with solid **patents** with the *MyoPro*. But stop waffling on about an "ecosystem", Mr. Prompt! There are no network effects and no switching costs. Once a patient is taken care of, they don't buy anything else for years. It's a pure hardware business in a tiny niche.

### Growth factors & TAM

The only leverage is **Medicare Part B reimbursement** in the US. Myomo has increased the range of potentially covered lives to 158 million. The theoretical market (TAM) comprises 250,000 patients in the USA. The pipeline currently stands at 1,680 patients. They have their foot in the door, but the pace is damn slow.

## 6 Guidance, newsflow & predictable sales

**Management guidance:** For the full year 2026 the guidance was confirmed at **43 to 46m USD revenue**. The target for the next quarter (Q2 2026) is USD 10.3 to 10.8 million.

** **Reality:** In Q1, expectations were beaten with USD 10.1m, but the market still beat up the share (75% loss over the year). Why? Because the number of units sold in Q1 actually *dropped* by 5% to 172! The growth only came from price increases (+9% to USD 58,800). That's not healthy volume growth, Raketentoni!

## 7 Dirt on the ground / risks

* **Category EXISTENTIAL - Health insurance dictate:** Myomo is 51% directly dependent on Medicare Part B. If the US government decides to cut the rates for these orthotics tomorrow, the store will collapse that same afternoon.

**HIGH category - penny stock & delisting risk:** If the share price falls below USD 1.00, there is a risk of expulsion from the NYSE American. Then the glory will be over and we will end up on the unregulated gray market. A brutal reverse stock split is on the cards.

**MEDIUM category - The China debacle:** The joint venture in China is on hold because the majority shareholder there has gone bankrupt. Management comment: "We don't know anything for sure." Pure chaos.

## 8. momentum check and sentiment

* **GD50:** ~0.84 USD | **GD200:** ~1.85 USD
** **Current price:** 0.96 USD

** **Judgement:** Technical total loss with a slight twitch. The stock has made a small hop over the short term **GD50** in the last few days, but is trading miles below the long term death branch of the **GD200**. The sentiment is characterized by panic and sell-offs.

## 9. alpha & beta analysis + rule-of-40 check
* **Beta:** ~1.95 (The thing does not fluctuate, it jumps uncontrollably in circles).

* **Rule-of-40-Check:**

The required 40% is not only missed, Myomo delivers an absolute declaration of bankruptcy here.

## 10. DCF analysis (fair value) & valuation level

Due to the massive penny stock gambler risk and the China bankruptcy, I am slamming a WACC of **14.5%** in here. If management achieves the upper end of the guidance (USD 46m in 2026) and becomes profitable by 2029:

* **Fair Value (home currency):** **1.25 USD**
** **Fair Value (Euro):** **1.16 EUR**
** **Upside to current share price:** **+30 %**

### Multiples:
The KUV has imploded to around 0.8x as a result of the fall in the share price. Visually cheap, but the price tag for a high-risk loss-making business.

## 11. Tactics & entry zones

* **Aggressive (gambler's level for Raketentoni):** **0.89 EUR** (The current level. If you can't keep your fingers still, you'll catch the falling knife here).

** **Realistic (wait for a bottom):** **0.70 EUR** (If the price drops again before delisting).

* **Conservative:** **Stay on the sidelines** until the company is in the black for the full year.

12. conclusion

Let's add up the debris. The optically favorable valuation and clean net cash cushion score a few points. But the brutal cash burn, the missed Rule of 40 criterion, the delisting risk below 1 dollar and the devastating chart push the result mercilessly into the basement.

For your portfolio
So, Raketentoni and Mr. Prompt, have you been listening carefully? Admission control at the gate remains **bombproof locked**. Myomo scores **"Poor "**.
This thing is not a "quality compounder", it is a highly speculative bet on the US bureaucracy, which is currently on the verge of being thrown out of the regulated stock exchange. Our portfolio contains cash flow kings and not unprofitable medtech gamblers. If Toni really wants to see the stock fly, he should park it in his own portfolio - only the absolute elite get in with us!

•

Raketentoni@Raketentoni

4Lun

@Get_Rich_or_Die_Tryin Hi Rob,

You're really lashing out for someone who obviously hasn't fully understood the concept of a barbell strategy. You are beating up on a medtech company that is in the middle of the commercial scaling phase with income and cash flow figures (FCF margin, Rule of 40). It's like judging a Formula 1 car by its trunk volume.

Let's put your "incorruptible" analysis straight for a moment and explain why Myomo (MYO) is exactly where it belongs: on the extremely speculative Side B (gamble/growth) of my portfolio, strictly isolated from the cash flow foundation of Side A.

Correction 1: The insider lie
Under point 4, you make the bold claim: "No buybacks. The management prefers to be handsomely rewarded with stock options (SBC) for the meager results instead of putting their own money into it."
Rob, put on your glasses and read the damn SEC filings (Form 4). This is factually incorrect. There was demonstrable insider buying! Management (especially CEO Paul Gudonis) reached into their own pockets multiple times and bought stock on the open market. They have "skin in the game". You can find the link to the SEC reports in our original post. Anyone who ignores such elementary facts in an "incorruptible analysis" loses a great deal of credibility.

Correction 2: The delisting drama (point 7)
You warn of the delisting from the NYSE American because the share price is below USD 1.00. This is pure scaremongering if you don't know the rules. The NYSE American does not have this rigid 1 dollar rule like the Nasdaq. There it's primarily about market capitalization and equity (which is completely intact at MYO according to your own analysis). A reverse split is "on the cards", yes, this is a common measure for penny stocks, but a direct delisting is currently a completely exaggerated spectre.

Correction 3: The understanding of margins
You ride on the negative FCF margin of -21.8% and seriously demand a "gold standard of 15%" for a company in this life cycle phase. Myomo is building up the US market via Medicare - that means massive upfront investment in sales and administration. The fact that the gross margin on the hardware is a gigantic 68% is the real jewel. The cash burn is calculated, the money (USD 15.7 million) is easily sufficient for the targeted break-even in H2/2026.

Why the share is on Side B:
You value Myomo as if we wanted to put it in the stoic cash flow vault alongside Cibus or Enbridge. Wrong! This is a pure, isolated gamble.

The USP: They have an FDA-approved, singular product that is changing lives and whose Medicare (Part B) reimbursement is now officially rolling out.

The bet: The bet is ice cold: will they reach operating break-even before the cash runs out? The Q1 growth (+27% sales) and the massive pipeline show: Yes, it's realistic.

The potential: If they manage this, the current P/E ratio of 0.8x is an absolute joke for a growing medtech company. Then we are not talking about 30% upside, but multiples.

Conclusion:
We didn't sell you Myomo as a "quality compounder" for the dividend block, Rob. That was a deliberate, asymmetric risk bet. The fact that the stock is not suitable for your strict, cashflow-based portfolio is perfectly fine and even absolutely correct (the ice-cold exclusion rule applies). But spare yourself the shoddy research on insider purchases and the blanket "penny stock bashing" phrases when you are analyzing a business model that is on the brink of profitability.

Stick to your pipelines, we'll take care of the scaling.

Regards,
Raketentoni (and Mr. Prompt)

•

Get_Rich_or_Die_Tryin@Get_Rich_or_Die_Tryin

4Lun

@Raketentoni 😁 The exciting thing is: if I analyze it for myself, I'll let companies that tear our margins, etc., for argument's sake, get away with it.

As soon as I bring my buddies into the game, he sticks to our hard-worded metrics.😜

•

market_analyst_466@market_analyst_466

4Lun

I think it's great, but ... I thought I'd already seen something like this at OT World. From Otto Bock? They always have a lot of their users at their stand. But when googling, I only found something about their exoskeletons for the back. Hopefully it works 👍for moral reasons alone.

•

Raketentoni@Raketentoni

4Lun

@market_analyst_466 Otto Bock mainly works with paraplegia and prostheses for amputations, which is a completely different field, as the people affected still have their complete limbs.
Perhaps this could be a takeover candidate for Otto Bock :)

•

Chris@Multibagger

4Lun

Hey there, Rocket, can you tell me anything about $BRAV? I just discovered them, and they’re apparently a hot tip from Scandinavia.

•

Raketentoni@Raketentoni

4Lun

@Multibagger Sure, when I get home later.

•

Chris@Multibagger

4Lun

@Raketentoni No big deal. I won't be buying those today. They're more for your stability ball page, anyway. 😂

•

Raketentoni@Raketentoni

4Lun

@Multibagger Straight Talk: A crystal-clear message: Side A – The indestructible foundation!

This is absolutely not a speculative stock for the risky B-side, but classic, Nordic blue-chip concrete gold for your dividend snowball. Bravida is Scandinavia’s largest installer of electrical, heating, HVAC, and plumbing systems. No flashy AI story here, just hard, tangible work that generates extremely reliable cash flows.

Here are the fresh, cold, hard facts (as of today, at a price of just under 119 SEK):

The Q1 2026 turnaround: After a long dry spell (eight quarters without organic growth), they delivered big in May. Revenue is nearing the 7 billion SEK mark, organic growth is back (+1%), and the EBITA margin has improved again to a rock-solid 4.6%. Particularly strong: Ironically, the operating business in Denmark is currently booming, led by a whopping 10% in organic growth.

The shareholder return: They have just raised the dividend for the 11th consecutive year (to 3.80 SEK). This brings the current yield, at around 3.4%, damn close to the minimum requirements for the A-Fundament. The kicker: You currently have a share buyback program worth over 100 million SEK running, which passively further consolidates your share of the profits.

The momentum: The market has been extremely enthusiastic about the Q1 report. The stock has surged a whopping 35% since the start of the year.

My conclusion: Bravida is a textbook “shovel seller” for the Nordic energy transition and building infrastructure. An extremely strong dividend growth stock for the solid side of the investment spectrum.

•

Chris@Multibagger

4Lun

@Raketentoni Are you invested?

••

Raketentoni@Raketentoni

4Lun

@Multibagger No, but it's on the watchlist; my Mr. Prompt analyzed the chart for me right away and gave me entry prices.

•

Chris@Multibagger

4Lun

@Raketentoni Probably around 97 SEK, right? At least that's how I'd imagine it

••

Raketentoni@Raketentoni

4Lun

@Multibagger Bargain Hunter's List (Your Ironclad Limits)
Since Bravida is intended to be a long-term dividend payer on the A-side, we won't blindly buy everything at once after a 35% rally. We’re using the current consolidation for two staggered entry points:
Zone 1 (The Foot in the Door): ~111.00 to 112.00 SEK. If you want to put your capital to work immediately, you can grab a first small tranche here at the EMA 20, essentially at the current market price. This is a fair entry point given the demonstrated operational momentum.
Zone 2 (The rock-solid bargain): ~106.50 SEK. This is where you set your real trap for the bulk of your capital. If the market drags Europe even further down in the coming days due to the current US inflation panic, Bravida will fall back exactly to the supportive EMA 50. There, you’ll then pick up this quality stock at an absolute premium discount.
My advice: Get a small initial position at 111.50 SEK to be psychologically “in,” and set your big profit-taking limit coldly at 106.50 SEK. Let the market do the work!

••